投资者可在2025年3月25日之前联系Schall律师事务所以获取更多信息。如您在上述期间内遭受损失，可点击链接参与诉讼。该刑事诉讼尚未获得认证，在认证之前您并未由律师代表。若选择不采取行动，您将只能作为缺席班级成员。

在近期举行的股东大会上，专注于前列腺癌治疗药物开发的ESSA Pharma Inc.（NASDAQ:EPIX）获得股东对所有提案的多数支持，包括董事选举和审计师任命。周二举行的会议股东出席率达42.55%。根据InvestingPro数据显示，该公司保持强劲的流动性状况，流动比率为33.12，表明短期财务状况良好。

Credit: Joel Maisonet In his solo Dummy in Diaspora, Esho Rasho takes us through the story of Essa (whose name means “Jesus” in Arabic, as he reminds us more than once), the U.S.-born child of ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit.

ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit ...

ESSA stock opened at $19.08 on Monday. The stock has a 50-day simple moving average of $20.56 and a two-hundred day simple moving average of $19.73. The company has a quick ratio of 0.94 ...

ESSA is a clinical stage pharmaceutical company that focuses on the development of small molecule drugs for the treatment of prostate cancer. At all relevant times the Company's lead product ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ESSA Bancorp, Inc. (NASDAQ: ESSA) to CNB Financial Corporation for 0.8547 shares of ...